Compare AUDC & CCCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | AUDC | CCCC |
|---|---|---|
| Founded | 1992 | 2015 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 247.7M | 404.7M |
| IPO Year | 2000 | 2020 |
| Metric | AUDC | CCCC |
|---|---|---|
| Price | $9.91 | $3.66 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 6 |
| Target Price | ★ $12.50 | $12.20 |
| AVG Volume (30 Days) | 103.5K | ★ 2.3M |
| Earning Date | 05-05-2026 | 05-06-2026 |
| Dividend Yield | ★ 4.54% | N/A |
| EPS Growth | N/A | ★ 16.45 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $35,947,000.00 |
| Revenue This Year | $4.24 | N/A |
| Revenue Next Year | $2.18 | N/A |
| P/E Ratio | $23.06 | ★ N/A |
| Revenue Growth | N/A | ★ 1.02 |
| 52 Week Low | $6.95 | $1.69 |
| 52 Week High | $10.86 | $5.17 |
| Indicator | AUDC | CCCC |
|---|---|---|
| Relative Strength Index (RSI) | 49.34 | 42.05 |
| Support Level | $8.62 | $3.40 |
| Resistance Level | $10.31 | $3.91 |
| Average True Range (ATR) | 0.25 | 0.23 |
| MACD | -0.00 | -0.05 |
| Stochastic Oscillator | 51.93 | 11.80 |
AudioCodes Ltd provides voice communications solutions for enterprises, contact centers, and service providers, including voice infrastructure, cloud-based platforms, and Voice AI applications. Its AudioCodes Live Platform is a cloud-based service delivery platform that enables provisioning, management, and operation of voice and AI-based communication services, including PSTN connectivity and integration with platforms such as Microsoft Teams, Webex Calling, and Zoom Phone. The company's solutions are organized into three layers: voice infrastructure and devices, cloud-based platforms, and Voice AI applications for contact center and productivity use cases. It also offers management tools such as One Voice Operations Center (OVOC), Device Manager, and AudioCodes Routing Manager (ARM).
C4 Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patient's lives. The Company is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. The degrader medicines of the company are designed to harness the body's natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, and drug undruggable targets and improve patient outcomes. Its pipeline is Cemsidomide, CFT8919, and other discovery products.